{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:13:23Z","timestamp":1780467203215,"version":"3.54.1"},"reference-count":61,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.jval.2018.07.880","type":"journal-article","created":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T01:21:06Z","timestamp":1536369666000},"page":"185-193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Assessing the Cost-Effectiveness of Updated Breast Cancer Screening Guidelines for Average-Risk Women"],"prefix":"10.1016","volume":"22","author":[{"given":"Ya-Chen","family":"Tina Shih","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2018.07.880_bib1","series-title":"Cancer Facts and Figures\u00a02018","year":"2018"},{"key":"10.1016\/j.jval.2018.07.880_bib2","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.2015.13183","article-title":"Benefits and harms of breast cancer screening: a systematic review","volume":"314","author":"Myers","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2018.07.880_bib3","doi-asserted-by":"crossref","first-page":"256","DOI":"10.7326\/M15-0970","article-title":"Harms of breast cancer screening: systematic review to update the 2009 U.S. Preventive Services Task Force recommendation","volume":"164","author":"Nelson","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jval.2018.07.880_bib4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.7326\/M15-2886","article-title":"Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement","volume":"164","author":"Siu","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jval.2018.07.880_bib5","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1001\/jama.2015.12783","article-title":"Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society","volume":"314","author":"Oeffinger","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2018.07.880_bib6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1158\/1055-9965.EPI-04-0499","article-title":"A\u00a0model-based comparison of breast cancer screening strategies: mammograms and clinical breast examinations","volume":"14","author":"Shen","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jval.2018.07.880_bib7","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1158\/1055-9965.EPI-08-0918","article-title":"Cost-effectiveness analysis of mammography and clinical breast examination strategies: a comparison with current guidelines","volume":"18","author":"Ahern","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jval.2018.07.880_bib8","series-title":"Probability, Statistics, and Modelling in Public Health","first-page":"405","article-title":"Optimization of breast cancer screening modalities","author":"Shen","year":"2006"},{"key":"10.1016\/j.jval.2018.07.880_bib9","series-title":"United States Cancer Statistics: 1999\u20132012 Incidence and Mortality Web-Based Report","year":"2015"},{"key":"10.1016\/j.jval.2018.07.880_bib10","doi-asserted-by":"crossref","first-page":"dju289","DOI":"10.1093\/jnci\/dju289","article-title":"Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality","volume":"106","author":"Munoz","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jval.2018.07.880_bib11","doi-asserted-by":"crossref","first-page":"126S","DOI":"10.1177\/0272989X17729358","article-title":"Modeling ductal carcinoma in situ (DCIS): an overview of CISNET model approaches","volume":"38","author":"van Ravesteyn","year":"2018","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2018.07.880_bib12","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1002\/1097-0142(19930601)71:11<3547::AID-CNCR2820711114>3.0.CO;2-C","article-title":"Age-dependent growth rate of primary breast cancer","volume":"71","author":"Peer","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.jval.2018.07.880_bib13","series-title":"SEER Cancer Statistics Review, 1975\u20132002","author":"Ries","year":"2005"},{"key":"10.1016\/j.jval.2018.07.880_bib14","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1002\/cncr.21030","article-title":"Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma","volume":"103","author":"Grann","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.jval.2018.07.880_bib15","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/oxfordjournals.aje.a010265","article-title":"Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status","volume":"151","author":"Huang","year":"2000","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jval.2018.07.880_bib16","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1200\/JCO.2002.09.023","article-title":"The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2","volume":"20","author":"Lakhani","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jval.2018.07.880_bib17","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1524-4741.2009.00822.x","article-title":"Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999\u20132004","volume":"15","author":"Parise","year":"2009","journal-title":"Breast J"},{"key":"10.1016\/j.jval.2018.07.880_bib18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.jval.2018.07.880_bib19","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1200\/JCO.2002.02.026","article-title":"Revision of the American Joint Committee on Cancer staging system for breast cancer","volume":"20","author":"Singletary","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jval.2018.07.880_bib20","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1056\/NEJMoa1600249","article-title":"Breast-cancer tumor size, overdiagnosis, and mammography screening effectiveness","volume":"375","author":"Welch","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jval.2018.07.880_bib21","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-155-8-201110180-00005","article-title":"Comparative effectiveness of digital versus film-screen mammography in community practice in the United States: a cohort study","volume":"155","author":"Kerlikowske","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jval.2018.07.880_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-148-1-200801010-00002","article-title":"Cost-effectiveness of digital mammography breast cancer screening","volume":"148","author":"Tosteson","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jval.2018.07.880_bib23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1148\/radiol.2512081235","article-title":"Full-field digital versus screen-film mammography: comparison within the UK breast screening program and systematic review of published data","volume":"251","author":"Vinnicombe","year":"2009","journal-title":"Radiology"},{"key":"10.1016\/j.jval.2018.07.880_bib24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1148\/radiol.2251011667","article-title":"Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations","volume":"225","author":"Kolb","year":"2002","journal-title":"Radiology"},{"key":"10.1016\/j.jval.2018.07.880_bib25","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/sim.2178","article-title":"Estimation of age-specific sensitivity and sojourn time in breast cancer screening studies","volume":"24","author":"Cong","year":"2005","journal-title":"Stat Med"},{"key":"10.1016\/j.jval.2018.07.880_bib26","doi-asserted-by":"crossref","first-page":"855","DOI":"10.7326\/0003-4819-133-11-200012050-00009","article-title":"Performance of screening mammography among women with and without a first-degree relative with breast cancer","volume":"133","author":"Kerlikowske","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jval.2018.07.880_bib27","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.breast.2013.02.013","article-title":"Is full-field digital mammography more accurate than screen-film mammography in overall population screening? A systematic review and meta-analysis","volume":"22","author":"Souza","year":"2013","journal-title":"Breast"},{"key":"10.1016\/j.jval.2018.07.880_bib28","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/jama.293.10.1245","article-title":"Screening for breast cancer","volume":"293","author":"Elmore","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2018.07.880_bib30","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1148\/radiol.2017161519","article-title":"National performance benchmarks for modern diagnostic digital mammography: update from the Breast Cancer Surveillance Consortium","volume":"283","author":"Sprague","year":"2017","journal-title":"Radiology"},{"key":"10.1016\/j.jval.2018.07.880_bib31","series-title":"Assessing and Improving the Interpretation of Breast Image: Workshop Summary","year":"2015"},{"key":"10.1016\/j.jval.2018.07.880_bib32","series-title":"Modeling in Medical Decision Making","author":"Parmigiani","year":"2002"},{"key":"10.1016\/j.jval.2018.07.880_bib33","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.1996.14.5.1589","article-title":"Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study","volume":"14","author":"Perloff","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jval.2018.07.880_bib34","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJM199405053301801","article-title":"Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma","volume":"330","author":"Wood","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jval.2018.07.880_bib35","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/BF01655185","article-title":"A\u00a0randomized trial of CMF versus CMFVP as adjuvant chemotherapy in women with node-positive stage II breast cancer: a CALGB study","volume":"9","author":"Wood","year":"1985","journal-title":"World J Surg"},{"key":"10.1016\/j.jval.2018.07.880_bib36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jncimonographs\/lgj003","article-title":"Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975\u20131999","author":"Mariotto","year":"2006","journal-title":"J\u00a0Natl Cancer Inst Monogr"},{"key":"10.1016\/j.jval.2018.07.880_bib37","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1634\/theoncologist.2008-0001","article-title":"Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Dahabreh","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.jval.2018.07.880_bib38","series-title":"Cost-Effectiveness in Health and Medicine","author":"Gold","year":"1996"},{"key":"10.1016\/j.jval.2018.07.880_bib39","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1524-4733.2009.00660.x","article-title":"Abbott TA IIIrd, et\u00a0al. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force Report\u2014part II","volume":"13","author":"Garrison","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2018.07.880_bib40","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1177\/0272989X12454577","article-title":"Modeling good research practices\u2014overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1","volume":"32","author":"Caro","year":"2012","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2018.07.880_bib41","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2018.07.880_bib42","series-title":"Physician Fee Schedule","year":"2017"},{"key":"10.1016\/j.jval.2018.07.880_bib43","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1001\/jama.295.20.2374","article-title":"Cost-effectiveness of screening BRCA1\/2 mutation carriers with breast magnetic resonance imaging","volume":"295","author":"Plevritis","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2018.07.880_bib44","series-title":"NCDB Benchmark Reports","year":"2016"},{"key":"10.1016\/j.jval.2018.07.880_bib45","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jnci\/djq495","article-title":"Projections of the cost of cancer care in the United States: 2010\u20132020","volume":"103","author":"Mariotto","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jval.2018.07.880_bib46","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/MLR.0b013e3181a2d847","article-title":"Overview of methods to estimate the medical costs of cancer","volume":"47","author":"Barlow","year":"2009","journal-title":"Med Care"},{"key":"10.1016\/j.jval.2018.07.880_bib47","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/jncimonographs\/lgt001","article-title":"Economic studies in colorectal cancer: challenges in measuring and comparing costs","volume":"2013","author":"Yabroff","year":"2013","journal-title":"J\u00a0Natl Cancer Inst Monogr"},{"key":"10.1016\/j.jval.2018.07.880_bib48","first-page":"697","article-title":"Economic\/societal burden of metastatic breast cancer: a US perspective","volume":"16","author":"Allen","year":"2010","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jval.2018.07.880_bib49","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1200\/JCO.2009.25.9655","article-title":"Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients","volume":"28","author":"Hershman","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jval.2018.07.880_bib50","series-title":"Medicare Part B Drug Average Sales Price, 2017 ASP Drug Pricing Files","year":"2017"},{"key":"10.1016\/j.jval.2018.07.880_bib51","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/bjc.2014.458","article-title":"Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk","volume":"111","author":"Ahern","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jval.2018.07.880_bib52","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/00005650-200006000-00004","article-title":"One thousand health-related quality-of-life estimates","volume":"38","author":"Tengs","year":"2000","journal-title":"Med Care"},{"key":"10.1016\/j.jval.2018.07.880_bib53","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"},{"key":"10.1016\/j.jval.2018.07.880_bib54","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/hec.635","article-title":"Representing uncertainty: the role of cost-effectiveness acceptability curves","volume":"10","author":"Fenwick","year":"2001","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2018.07.880_bib55","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hec.1481","article-title":"International survey on willingness-to-pay (WTP) for one additional QALY gained: What is the threshold of cost effectiveness?","volume":"19","author":"Shiroiwa","year":"2010","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2018.07.880_bib56","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jval.2018.07.880_bib57","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7326\/M15-1536","article-title":"Collaborative modeling of the benefits and harms associated with different U.S. breast cancer screening strategies","volume":"164","author":"Mandelblatt","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jval.2018.07.880_bib58","doi-asserted-by":"crossref","first-page":"738","DOI":"10.7326\/0003-4819-151-10-200911170-00010","article-title":"Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms","volume":"151","author":"Mandelblatt","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jval.2018.07.880_bib59","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/jamaoncol.2015.3084","article-title":"Breast tumor prognostic characteristics and biennial vs annual mammography, age, and menopausal status","volume":"1","author":"Miglioretti","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jval.2018.07.880_bib60","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1470-2045(13)70134-7","article-title":"Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): a prospective comparison study","volume":"14","author":"Ciatto","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jval.2018.07.880_bib61","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jamainternmed.2014.981","article-title":"Consequences of false-positive screening mammograms","volume":"174","author":"Tosteson","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jval.2018.07.880_bib62","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/00005650-200006000-00004","article-title":"One thousand health-related quality-of-life estimates","volume":"38","author":"Tengs","year":"2000","journal-title":"Med Care"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301518332376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301518332376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:15:53Z","timestamp":1761095753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301518332376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S1098301518332376"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2018.07.880","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing the Cost-Effectiveness of Updated Breast Cancer Screening Guidelines for Average-Risk Women","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2018.07.880","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}